- Represented Advaxis Inc., a biopharmaceutical company developing immunotherapies, in a clinical collaboration and licensing deal with Amgen Inc. for a preclinical candidate involving $65 million in upfront cash and equity investment with $475 million in development, regulatory and sales milestones and tiered royalties on net sales.
- Developed patent strategies for and managed domestic and international patent portfolios related to genome editing, CRISPR-Cas technology, and transgenic organisms for a leading biopharmaceutical company.
- Developed patent strategies for and managed domestic and international patent portfolios related to cancer immunotherapies for a clinical stage biotechnology company.
- Developed patent strategies for and managed domestic and international patent portfolios related to transgenic plants for an agricultural biotechnology company.
- Developed patent strategies for patent applications related to diagnostic assays for a biotechnology company.
- Counseled a clinical stage biotechnology company on therapeutic life cycle management and patent strategies.
Stephen H. Schilling, Ph.D.
Partner,
- Phone: +1 919 862 2225
- Email: steve.schilling@alston.com
Steve builds strong relationships with clients by being responsive to their needs and developing strategies tailored to those needs. Steve uses his Ph.D. in pharmacology and his experience in molecular biology, cancer biology, immunology, and agricultural biotechnology to provide his clients with the knowledge and guidance they seek throughout the life of their patent portfolios.